The global meningococcal vaccines market value was USD 3.45 billion in 2022, driven by the increasing prevalence of meningococcal disease across the globe. The market size is anticipated to grow at a CAGR of 6.8% during the forecast period of 2023-2031 to achieve a value of USD 6.24 billion by 2031.
Several factors contribute to the market expansion. First, governments and healthcare organizations are implementing robust immunization programs to prevent meningococcal infections. This includes the incorporation of meningococcal vaccines into national immunization schedules and the promotion of routine vaccination for at-risk populations. This focus on immunization is creating a favourable market environment for meningococcal vaccines.
Geographically, the market for meningococcal vaccines is witnessing growth across regions. Developed countries have well-established immunization programs, while developing countries are expanding their vaccination efforts to combat the disease burden. Additionally, travel-related vaccinations and initiatives aimed at preventing outbreaks in high-risk areas contribute to the market growth.
Introduction
Meningococcal vaccines are designed to protect against meningococcal disease, which is caused by the bacterium Neisseria meningitidis. Meningococcal disease can lead to meningitis (inflammation of the membranes surrounding the brain and spinal cord) and septicemia (bloodstream infection), both of which can be life-threatening. Meningococcal vaccines stimulate the immune system to produce an immune response against the bacteria, providing protection against the disease.Key Trends in the Meningococcal Vaccines Market
Some key trends involved in the meningococcal vaccines market are as follows:- Increasing Global Immunization Efforts: There is a growing emphasis on immunization programs worldwide to combat meningococcal disease. Governments and healthcare organizations are promoting routine immunization of infants and adolescents to reduce the incidence of the disease. This trend is driven by the recognition of the public health impact of meningococcal infections and the availability of effective vaccines
- Expansion of Vaccine Coverage: In recent years, there has been an expansion in the number of countries including meningococcal vaccines in their national immunization schedules. This includes both developed and developing countries, with an aim to protect vulnerable populations and prevent outbreaks. The focus is on providing access to vaccines to those at highest risk, such as infants, adolescents, and individuals living in high-risk areas or participating in certain activities (e.g., travel, military service)
- Advancements in Vaccine Technology: The development of new meningococcal vaccines and advancements in vaccine technology are driving the market. These include the introduction of conjugate vaccines, which offer broader protection against multiple serogroups of Neisseria meningitidis. Conjugate vaccines have demonstrated enhanced immunogenicity and longer-lasting protection compared to earlier generations of vaccines. Additionally, efforts are underway to develop vaccines that provide protection against emerging serogroups and to improve the efficacy and duration of immune response
- Focus on Serogroup B Vaccines: Serogroup B of Neisseria meningitidis has historically posed a challenge for vaccine development due to its complex polysaccharide structure. However, there have been significant advancements in the development of serogroup B vaccines, including the use of novel approaches such as recombinant protein-based vaccines and outer membrane vesicle vaccines. This has opened up new possibilities for providing protection against this particular serogroup
Meningococcal Vaccines Market Segmentations
Market Breakup by Type
- Mono Vaccines
- Combination Vaccines
Market Breakup by Age Group
- Infants
- Childrens
- Adults
Market Breakup by Brand
- Menactra
- Menveo
- Nimenrix
- Trumenba
- Bexsero
- Others
Market Breakup by End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- Others
Market Breakup by Region
North America
- United States of America
- Canada
Europe
- United Kingdom
- Germany
- France
- Italy
- Others
Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
Latin America
- Brazil
- Argentina
- Mexico
- Others
Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Meningococcal Vaccines Market Scenario
The global market for meningococcal vaccines is experiencing significant growth due to the increasing incidence of meningococcal disease and the growing awareness about the importance of vaccination. Meningococcal disease is a serious public health concern, and the demand for effective vaccines is driving the market growth.Several factors contribute to the market expansion. First, governments and healthcare organizations are implementing robust immunization programs to prevent meningococcal infections. This includes the incorporation of meningococcal vaccines into national immunization schedules and the promotion of routine vaccination for at-risk populations. This focus on immunization is creating a favourable market environment for meningococcal vaccines.
Geographically, the market for meningococcal vaccines is witnessing growth across regions. Developed countries have well-established immunization programs, while developing countries are expanding their vaccination efforts to combat the disease burden. Additionally, travel-related vaccinations and initiatives aimed at preventing outbreaks in high-risk areas contribute to the market growth.
Meningococcal Vaccines Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:- Johnson & Johnson Private Limited
- Mylan N.V
- Sun Pharmaceutical Industries Limited
- Sanofi S.A
- Merck & Co., Inc
- GSK plc
- Novartis AG
- AbbVie Inc
- Fresenius Kabi AG
- Amneal Pharmaceuticals LLC
- Pfizer Inc
- Serum Institute of India Pvt. Ltd
- Incepta Pharmaceuticals Ltd
- Walvax Biotechnology Co., Ltd
- Bio-Manguinhos
Table of Contents
1 Preface
3 Global Meningococcal Vaccines Market Overview
4 Global Meningococcal Vaccines Market Landscape
5 Global Meningococcal Vaccines Market Dynamics
6 Global Meningococcal Vaccines Market Segmentation
7 North America Meningococcal Vaccines Market
8 Europe Meningococcal Vaccines Market
9 Asia Pacific Meningococcal Vaccines Market
10 Latin America Meningococcal Vaccines Market
11 Middle East and Africa Meningococcal Vaccines Market
12 Patent Analysis
13 Grants Analysis
14 Funding Analysis
15 Partnership and Collaborations Analysis
16 Regulatory Framework
17 Supplier Landscape
18 Global Meningococcal Vaccines Market - Distribution Model (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
21 Payment Methods (Additional Insight)
Companies Mentioned
- Johnson & Johnson Private Limited
- Mylan N.V.
- Sun Pharmaceutical Industries Limited
- Sanofi S.A.
- Merck & Co. Inc.
- GSK plc.
- Novartis AG
- AbbVie Inc.
- Fresenius Kabi AG
- Amneal Pharmaceuticals LLC.
- Pfizer Inc.
- Serum Institute of India Pvt. Ltd. Incepta Pharmaceuticals Ltd.
- Walvax Biotechnology Co. Ltd.
- Bio-Manguinhos
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 147 |
| Published | May 2023 |
| Forecast Period | 2023 - 2031 |
| Estimated Market Value ( USD | $ 3.69 Billion |
| Forecasted Market Value ( USD | $ 6.24 Billion |
| Compound Annual Growth Rate | 6.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 14 |
